Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Resectable NSCLC

IASLC Webinars Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Respectable NSCLC
Overview

Immune checkpoint inhibitors and EGFR-TKIs, which have shown efficacy in advanced lung cancer, are now being applied to perioperative treatment. Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. In this webinar, we would like to deepen the discussion on immune checkpoint inhibitors in the perioperative setting.

This is the joint webinar between IASLC and JLCS (Japan Lung Cancer Society, https://www.haigan.gr.jp/). This webinar will consist of a 20-minute presentation from the keynote speaker, Dr. Enriqueta Felip, given in English, followed by a 25-minute panel discussion conducted in Japanese with 15-minutes at the end for Q&A.

 

 

 

Date
Apr 26, 2022 -
Apr 26, 2022

April 26, 2022, at 4:00 AM Mountain Time; 7:00 PM Japan Time; 11:00 AM Central European Time 

At the end of the webinar, learners will be able to:  

1.  understand current standards of perioperative treatment in resectable NSCLC

2.  understand candidates for future standard therapy of perioperative treatment

3.  discuss appropriate indication of perioperative treatment including immune checkpoint inhibitors

 

To improve knowledge of current standards and future candidates of perioperative therapy to promote better outcome in patients with resectable NSCLC.

 

This webinar is designed to meet the educational needs of physicians and researchers specializing in medical oncology, thoracic surgery, and radiation oncology. To meet the needs of both international and Japanese audiences, the keynote will be provided in English and the panel discussion in Japanese.

April 26, 2022, at 4:00 AM Mountain Time; 7:00 PM Japan Time; 11:00 AM Central European Time 

At the end of the webinar, learners will be able to:  

1.  understand current standards of perioperative treatment in resectable NSCLC

2.  understand candidates for future standard therapy of perioperative treatment

3.  discuss appropriate indication of perioperative treatment including immune checkpoint inhibitors

 

To improve knowledge of current standards and future candidates of perioperative therapy to promote better outcome in patients with resectable NSCLC.

 

This webinar is designed to meet the educational needs of physicians and researchers specializing in medical oncology, thoracic surgery, and radiation oncology. To meet the needs of both international and Japanese audiences, the keynote will be provided in English and the panel discussion in Japanese.

Share

Participants

Hidehito Horinouchi
Hidehito Horinouchi
Department of Thoracic Oncology
National Cancer Center Hospital
Dr. Tetsuya Mitsudomi
Tetsuya Mitsudomi
Department of Surgery, Division of Thoracic Surgery
Kindai University Faculty of Medicine
Dr. Enriqueta Felip
Enriqueta Felip
Section in Chief, Medical Oncology Department Vall d’Hebron University Hospital
Head, Thoracic Oncology and H&N Cancer Unit Vall d’Hebron University Hospital
Professor of Medicine, UVic-UCC
Yasushi Yatabe, MD, PhD
Yasushi Yatabe
Department of Diagnostic Pathology
National Cancer Center Hospital
Dr. Hirotsugu Kenmotsu
Hirotsugu Kenmotsu
Division of Thoracic Oncology
Shizuoka Cancer Center
Yasuhiro Tsutatni
Yasuhiro Tsutatni

MD, PhD

Department of Surgical Oncology
Research Institute for Radiation Biology and Medicine Hiroshima University